Bill Ackman, who has to do something huge to be in the press every single week or else he’ll get wrinkles and will need that Botox thing he’s trying to take over, has announced his Pershing Square Holdings hopes to raise $2 billion from a listing on the Euronext Amsterdam Stock Exchange.
He predicts the value will be $5 billion priced at $25 per share. Pershing Square said it has commitments of $1.5 billion from 30 cornerstone investors, and as of now has over 300 investors. UBS and Deutsche Bank are expected to run the listing with Credit Suisse acting as bookrunner. Pershing Square has done well in 2014, rising 31%.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
When Bill Ackman isn’t seeking listings on overseas exchanges, he spends his time trying to destroy Herbalife, because he has a short position and thinks it is much, much worse than Tupperware, and convincing Botox-maker Allergan that it really wants to be seduced by a hostile bid for budget-slashing Valeant.
All in a day’s work for Pershing Square.
